(RTTNews) - Exact Sciences Corp. (EXAS) Monday has introduced Cologuard Plus, an FDA-approved noninvasive colorectal cancer - CRC screening test for average-risk adults aged 45 and older. It offers 95 ...
Forbes contributors publish independent expert analyses and insights. Physician who writes about the rising rates of cancer in young adults. This voice experience is generated by AI. Learn more. This ...
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded partnership with Humana Inc. to enhance ...
Studies show higher completion rates for mt-sDNA testing and the positive impact of patient navigation in expanding access to underserved and older populations “Exact Sciences’ research at ACG 2025 ...
Anne grew up in a small farm town in southeast Nebraska, where her upbringing was filled with lessons on problem solving, teamwork and the importance of giving back. These qualities have carried her ...
Positive and Negative Predictive Value of a Non-Endoscopic Molecular Barrett’s Esophagus Detection Test in Screening Eligible Adults: Results from a Large Multicenter Population Based Clinical Trial ...
The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date Building ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results